JPWO2019243850A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019243850A5 JPWO2019243850A5 JP2020571700A JP2020571700A JPWO2019243850A5 JP WO2019243850 A5 JPWO2019243850 A5 JP WO2019243850A5 JP 2020571700 A JP2020571700 A JP 2020571700A JP 2020571700 A JP2020571700 A JP 2020571700A JP WO2019243850 A5 JPWO2019243850 A5 JP WO2019243850A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- oxadiazole
- azabicyclo
- octane
- diazaspiro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 R4 is an H Chemical group 0.000 claims description 126
- 150000001875 compounds Chemical class 0.000 claims description 58
- 229910052757 nitrogen Inorganic materials 0.000 claims description 54
- 150000002430 hydrocarbons Chemical group 0.000 claims description 46
- 125000005842 heteroatom Chemical group 0.000 claims description 38
- 125000002950 monocyclic group Chemical group 0.000 claims description 36
- 229910052760 oxygen Inorganic materials 0.000 claims description 34
- 150000003839 salts Chemical class 0.000 claims description 33
- 229910052717 sulfur Inorganic materials 0.000 claims description 30
- 125000002619 bicyclic group Chemical group 0.000 claims description 23
- 125000003118 aryl group Chemical group 0.000 claims description 18
- 125000001153 fluoro group Chemical group F* 0.000 claims description 18
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 229930195734 saturated hydrocarbon Natural products 0.000 claims description 16
- DPBWFNDFMCCGGJ-UHFFFAOYSA-N 4-Piperidine carboxamide Chemical compound NC(=O)C1CCNCC1 DPBWFNDFMCCGGJ-UHFFFAOYSA-N 0.000 claims description 14
- 239000001257 hydrogen Substances 0.000 claims description 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 14
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 125000004432 carbon atom Chemical group C* 0.000 claims description 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 12
- 125000001424 substituent group Chemical group 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 150000002367 halogens Chemical class 0.000 claims description 10
- 230000003647 oxidation Effects 0.000 claims description 10
- 238000007254 oxidation reaction Methods 0.000 claims description 10
- 125000004043 oxo group Chemical group O=* 0.000 claims description 10
- 125000004429 atom Chemical group 0.000 claims description 6
- 208000010877 cognitive disease Diseases 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- YNMZZHPSYMOGCI-UHFFFAOYSA-N undecan-3-one Chemical compound CCCCCCCCC(=O)CC YNMZZHPSYMOGCI-UHFFFAOYSA-N 0.000 claims description 6
- GACQWNAPVBCFQM-UHFFFAOYSA-N O=CN1C2(CCC2)CC1 Chemical compound O=CN1C2(CCC2)CC1 GACQWNAPVBCFQM-UHFFFAOYSA-N 0.000 claims description 5
- VVQIDZOAUIQOKY-UHFFFAOYSA-N 8-[1-(3-methyl-1,2,4-oxadiazol-5-yl)azepan-4-yl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one Chemical compound CC1=NOC(=N1)N1CCC(CCC1)N1CCC2(CNC(O2)=O)CC1 VVQIDZOAUIQOKY-UHFFFAOYSA-N 0.000 claims description 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 4
- 208000028698 Cognitive impairment Diseases 0.000 claims description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 125000004122 cyclic group Chemical group 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 239000011737 fluorine Chemical group 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- BKIMMITUMNQMOS-UHFFFAOYSA-N nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 claims description 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 3
- 230000003551 muscarinic effect Effects 0.000 claims description 3
- 239000000018 receptor agonist Substances 0.000 claims description 3
- 229940044601 receptor agonist Drugs 0.000 claims description 3
- KBGJSKZARWJVRK-BHWOMJMDSA-N (5S)-5-ethyl-1-[1-[1-(3-methyl-1,2,4-oxadiazol-5-yl)azepan-4-yl]piperidin-4-yl]pyrrolidin-2-one Chemical compound C(C)[C@H]1CCC(N1C1CCN(CC1)C1CCN(CCC1)C1=NC(=NO1)C)=O KBGJSKZARWJVRK-BHWOMJMDSA-N 0.000 claims description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 2
- KZKRRZFCAYOXQE-UHFFFAOYSA-N 1$l^{2}-azinane Chemical group C1CC[N]CC1 KZKRRZFCAYOXQE-UHFFFAOYSA-N 0.000 claims description 2
- RXBQCPFNLGINPW-UHFFFAOYSA-N 1'-[1-(3-methyl-1,2,4-oxadiazol-5-yl)azepan-4-yl]spiro[1H-indole-3,4'-piperidine]-2-one Chemical compound CC1=NOC(=N1)N1CCC(CCC1)N1CCC2(CC1)C(NC1=CC=CC=C12)=O RXBQCPFNLGINPW-UHFFFAOYSA-N 0.000 claims description 2
- WHALLMCIWBGPLM-UHFFFAOYSA-N 1-(cyclopropylmethyl)-8-[8-(3-methyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl]-2,8-diazaspiro[4.5]decan-3-one Chemical compound C1(CC1)CC1NC(CC11CCN(CC1)C1CC2CCC(C1)N2C1=NC(=NO1)C)=O WHALLMCIWBGPLM-UHFFFAOYSA-N 0.000 claims description 2
- WYFHOGNDYHEHBV-UHFFFAOYSA-N 1-benzyl-8-[1-(3-methyl-1,2,4-oxadiazol-5-yl)azepan-4-yl]-2,8-diazaspiro[4.5]decan-3-one Chemical compound C(C1=CC=CC=C1)C1NC(CC11CCN(CC1)C1CCN(CCC1)C1=NC(=NO1)C)=O WYFHOGNDYHEHBV-UHFFFAOYSA-N 0.000 claims description 2
- NBQJTNRPHKHLCM-UHFFFAOYSA-N 1-cyclopropyl-8-[8-(3-methyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl]-2,8-diazaspiro[4.5]decan-3-one Chemical compound C1(CC1)C1NC(CC11CCN(CC1)C1CC2CCC(C1)N2C1=NC(=NO1)C)=O NBQJTNRPHKHLCM-UHFFFAOYSA-N 0.000 claims description 2
- XJLDYKIEURAVBW-UHFFFAOYSA-N 3-decanone Chemical compound CCCCCCCC(=O)CC XJLDYKIEURAVBW-UHFFFAOYSA-N 0.000 claims description 2
- MIBJKUUVELZNJP-UHFFFAOYSA-N 3-methyl-5-[2-(4-pyrazol-1-ylpiperidin-1-yl)-6-azaspiro[3.4]octan-6-yl]-1,2,4-oxadiazole Chemical compound CC1=NOC(=N1)N1CC2(CC(C2)N2CCC(CC2)N2N=CC=C2)CC1 MIBJKUUVELZNJP-UHFFFAOYSA-N 0.000 claims description 2
- KLWSNZQBPQFATF-UHFFFAOYSA-N 3-methyl-5-[3-(4-pyrazol-1-ylpiperidin-1-yl)-6-azabicyclo[3.2.1]octan-6-yl]-1,2,4-oxadiazole Chemical compound CC1=NOC(=N1)N1C2CC(CC(C1)C2)N1CCC(CC1)N1N=CC=C1 KLWSNZQBPQFATF-UHFFFAOYSA-N 0.000 claims description 2
- JOAOVJYHNMBLLD-UHFFFAOYSA-N 3-methyl-5-[3-(4-pyrazol-1-ylpiperidin-1-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1,2,4-oxadiazole Chemical compound CC1=NOC(=N1)N1C2CC(CC1CC2)N1CCC(CC1)N1N=CC=C1 JOAOVJYHNMBLLD-UHFFFAOYSA-N 0.000 claims description 2
- XCTRZAFYYZWZKS-UHFFFAOYSA-N 3-methyl-5-[4-(4-pyrazol-1-ylpiperidin-1-yl)azepan-1-yl]-1,2,4-oxadiazole Chemical compound CC1=NOC(=N1)N1CCC(CCC1)N1CCC(CC1)N1N=CC=C1 XCTRZAFYYZWZKS-UHFFFAOYSA-N 0.000 claims description 2
- REKRVKAPQNABCS-UHFFFAOYSA-N 3-methyl-5-[4-(4-pyrazol-1-ylpiperidin-1-yl)piperidin-1-yl]-1,2,4-oxadiazole Chemical compound CC1=NOC(=N1)N1CCC(CC1)N1CCC(CC1)N1N=CC=C1 REKRVKAPQNABCS-UHFFFAOYSA-N 0.000 claims description 2
- PGLVGCOKZJKJMW-UHFFFAOYSA-N 3-methyl-5-[5-(4-pyrazol-1-ylpiperidin-1-yl)-2-azabicyclo[2.2.2]octan-2-yl]-1,2,4-oxadiazole Chemical compound CC1=NOC(=N1)N1C2CC(C(C1)CC2)N1CCC(CC1)N1N=CC=C1 PGLVGCOKZJKJMW-UHFFFAOYSA-N 0.000 claims description 2
- IKOCEWLCJSEBOG-UHFFFAOYSA-N 3-methyl-5-[6-(4-pyrazol-1-ylpiperidin-1-yl)-2-azaspiro[3.3]heptan-2-yl]-1,2,4-oxadiazole Chemical compound CC1=NOC(=N1)N1CC2(C1)CC(C2)N1CCC(CC1)N1N=CC=C1 IKOCEWLCJSEBOG-UHFFFAOYSA-N 0.000 claims description 2
- HNZLSDUORCLLFS-UHFFFAOYSA-N 3-methyl-5-[6-(4-pyrazol-1-ylpiperidin-1-yl)-2-azaspiro[3.4]octan-2-yl]-1,2,4-oxadiazole Chemical compound CC1=NOC(=N1)N1CC2(C1)CC(CC2)N1CCC(CC1)N1N=CC=C1 HNZLSDUORCLLFS-UHFFFAOYSA-N 0.000 claims description 2
- XGQADXPKVKUZHI-UHFFFAOYSA-N 3-methyl-5-[6-(4-pyrazol-1-ylpiperidin-1-yl)-3-azabicyclo[3.1.1]heptan-3-yl]-1,2,4-oxadiazole Chemical compound CC1=NOC(=N1)N1CC2C(C(C1)C2)N1CCC(CC1)N1N=CC=C1 XGQADXPKVKUZHI-UHFFFAOYSA-N 0.000 claims description 2
- JLAKCHGEEBPDQI-UHFFFAOYSA-N 4-(4-fluorobenzyl)piperidine Chemical compound C1=CC(F)=CC=C1CC1CCNCC1 JLAKCHGEEBPDQI-UHFFFAOYSA-N 0.000 claims description 2
- RPBGOCYDBHJHNN-UHFFFAOYSA-N 4-(cyclopropylmethyl)-8-[8-(3-methyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one Chemical compound C1(CC1)CC1NC(OC11CCN(CC1)C1CC2CCC(C1)N2C1=NC(=NO1)C)=O RPBGOCYDBHJHNN-UHFFFAOYSA-N 0.000 claims description 2
- NNDVXPYWQABDIC-UHFFFAOYSA-N 4-benzyl-8-[2-(3-methyl-1,2,4-oxadiazol-5-yl)-2-azaspiro[3.3]heptan-6-yl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one Chemical compound C(C1=CC=CC=C1)C1NC(OC11CCN(CC1)C1CC2(CN(C2)C2=NC(=NO2)C)C1)=O NNDVXPYWQABDIC-UHFFFAOYSA-N 0.000 claims description 2
- QIDVIFBZGIVZES-UHFFFAOYSA-N 4-cyclopropyl-8-[8-(3-methyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one Chemical compound C1(CC1)C1NC(OC11CCN(CC1)C1CC2CCC(C1)N2C1=NC(=NO1)C)=O QIDVIFBZGIVZES-UHFFFAOYSA-N 0.000 claims description 2
- QAIHPKHMUQRGFR-UHFFFAOYSA-N 4-ethyl-8-[1-(3-methyl-1,2,4-oxadiazol-5-yl)azepan-4-yl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one Chemical compound C(C)C1NC(OC11CCN(CC1)C1CCN(CCC1)C1=NC(=NO1)C)=O QAIHPKHMUQRGFR-UHFFFAOYSA-N 0.000 claims description 2
- ZXEKVMZBVBTWRU-UHFFFAOYSA-N 4-methyl-8-[8-(3-methyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one Chemical compound CC1NC(OC11CCN(CC1)C1CC2CCC(C1)N2C1=NC(=NO1)C)=O ZXEKVMZBVBTWRU-UHFFFAOYSA-N 0.000 claims description 2
- ONOPFFFCOXKFMF-UHFFFAOYSA-N 5-(8-azabicyclo[3.2.1]octan-8-yl)-3-(trifluoromethyl)-1,2,4-oxadiazole Chemical compound C1C2CCC(N2C=2ON=C(N=2)C(F)(F)F)CC1 ONOPFFFCOXKFMF-UHFFFAOYSA-N 0.000 claims description 2
- XRAPKCLPZGZIHP-UHFFFAOYSA-N 8-[1-(3-methyl-1,2,4-oxadiazol-5-yl)azepan-4-yl]-2,8-diazaspiro[4.5]decan-3-one Chemical compound CC1=NOC(=N1)N1CCC(CCC1)N1CCC2(CC(NC2)=O)CC1 XRAPKCLPZGZIHP-UHFFFAOYSA-N 0.000 claims description 2
- BZAKURPZDHSZIX-UHFFFAOYSA-N 8-[1-[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]azepan-4-yl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one Chemical compound FC(C1=NOC(=N1)N1CCC(CCC1)N1CCC2(CNC(O2)=O)CC1)(F)F BZAKURPZDHSZIX-UHFFFAOYSA-N 0.000 claims description 2
- NFOCDEOOKHQVLO-UHFFFAOYSA-N 8-[1-[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]azepan-4-yl]-2,8-diazaspiro[4.5]decan-3-one Chemical compound FC(C1=NOC(=N1)N1CCC(CCC1)N1CCC2(CC(NC2)=O)CC1)(F)F NFOCDEOOKHQVLO-UHFFFAOYSA-N 0.000 claims description 2
- AXDPXNOJVNVYQR-UHFFFAOYSA-N 8-[2-(3-methyl-1,2,4-oxadiazol-5-yl)-2-azabicyclo[2.2.2]octan-5-yl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one Chemical compound CC1=NOC(=N1)N1C2CC(C(C1)CC2)N1CCC2(CNC(O2)=O)CC1 AXDPXNOJVNVYQR-UHFFFAOYSA-N 0.000 claims description 2
- LRGNHEIWPSKWLZ-UHFFFAOYSA-N 8-[6-[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]-6-azabicyclo[3.2.1]octan-3-yl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one Chemical compound FC(C1=NOC(=N1)N1C2CC(CC(C1)C2)N1CCC2(CNC(O2)=O)CC1)(F)F LRGNHEIWPSKWLZ-UHFFFAOYSA-N 0.000 claims description 2
- PWZFXTGMJHMZPI-UHFFFAOYSA-N 8-[8-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one Chemical compound C1(CC1)C1=NOC(=N1)N1C2CC(CC1CC2)N1CCC2(CNC(O2)=O)CC1 PWZFXTGMJHMZPI-UHFFFAOYSA-N 0.000 claims description 2
- TWYWAXDQGCCUFI-UHFFFAOYSA-N 8-[8-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl]-2,8-diazaspiro[4.5]decan-3-one Chemical compound C1(CC1)C1=NOC(=N1)N1C2CC(CC1CC2)N1CCC2(CC(NC2)=O)CC1 TWYWAXDQGCCUFI-UHFFFAOYSA-N 0.000 claims description 2
- SPIHTFMRNLJGDD-UHFFFAOYSA-N 8-[8-(3-ethyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one Chemical compound C(C)C1=NOC(=N1)N1C2CC(CC1CC2)N1CCC2(CNC(O2)=O)CC1 SPIHTFMRNLJGDD-UHFFFAOYSA-N 0.000 claims description 2
- MTTOBLPLLNDSAE-UHFFFAOYSA-N 8-[8-(3-methyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one Chemical compound CC1=NOC(=N1)N1C2CC(CC1CC2)N1CCC2(CNC(O2)=O)CC1 MTTOBLPLLNDSAE-UHFFFAOYSA-N 0.000 claims description 2
- RIHLYAITXJUFMQ-UHFFFAOYSA-N 8-[8-(3-methyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl]-1-propan-2-yl-2,8-diazaspiro[4.5]decan-3-one Chemical compound C(C)(C)C1NC(CC11CCN(CC1)C1CC2CCC(C1)N2C1=NC(=NO1)C)=O RIHLYAITXJUFMQ-UHFFFAOYSA-N 0.000 claims description 2
- CEFMINOVHRWRIS-UHFFFAOYSA-N 8-[8-(3-methyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl]-4-propan-2-yl-1-oxa-3,8-diazaspiro[4.5]decan-2-one Chemical compound C(C)(C)C1NC(OC11CCN(CC1)C1CC2CCC(C1)N2C1=NC(=NO1)C)=O CEFMINOVHRWRIS-UHFFFAOYSA-N 0.000 claims description 2
- RLIRQTWMWGCPHL-UHFFFAOYSA-N 8-[8-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one Chemical compound C(C)(C)C1=NOC(=N1)N1C2CC(CC1CC2)N1CCC2(CNC(O2)=O)CC1 RLIRQTWMWGCPHL-UHFFFAOYSA-N 0.000 claims description 2
- PIRMCKRHUWNHIJ-UHFFFAOYSA-N 8-[8-[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]-8-azabicyclo[3.2.1]octan-3-yl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one Chemical compound FC(C1=NOC(=N1)N1C2CC(CC1CC2)N1CCC2(CNC(O2)=O)CC1)(F)F PIRMCKRHUWNHIJ-UHFFFAOYSA-N 0.000 claims description 2
- OCACSRBOUZWLHI-UHFFFAOYSA-N 8-[8-[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]-8-azabicyclo[3.2.1]octan-3-yl]-2,8-diazaspiro[4.5]decan-3-one Chemical compound FC(C1=NOC(=N1)N1C2CC(CC1CC2)N1CCC2(CC(NC2)=O)CC1)(F)F OCACSRBOUZWLHI-UHFFFAOYSA-N 0.000 claims description 2
- ZQIHVCAOEDZERM-UHFFFAOYSA-N 9-(3-methyl-1,2,4-oxadiazol-5-yl)-7-(4-pyrazol-1-ylpiperidin-1-yl)-3-oxa-9-azabicyclo[3.3.1]nonane Chemical compound CC1=NOC(=N1)N1C2COCC1CC(C2)N1CCC(CC1)N1N=CC=C1 ZQIHVCAOEDZERM-UHFFFAOYSA-N 0.000 claims description 2
- HTUAKUCQILXEBR-UHFFFAOYSA-N 9-[1-(3-methyl-1,2,4-oxadiazol-5-yl)azepan-4-yl]-1-oxa-3,9-diazaspiro[4.6]undecan-2-one Chemical compound CC1=NOC(=N1)N1CCC(CCC1)N1CCC2(CNC(O2)=O)CCC1 HTUAKUCQILXEBR-UHFFFAOYSA-N 0.000 claims description 2
- PPDPCGDPIJUVEF-UHFFFAOYSA-N 9-[1-(3-methyl-1,2,4-oxadiazol-5-yl)azepan-4-yl]-2,9-diazaspiro[4.6]undecan-3-one Chemical compound CC1=NOC(=N1)N1CCC(CCC1)N1CCC2(CC(NC2)=O)CCC1 PPDPCGDPIJUVEF-UHFFFAOYSA-N 0.000 claims description 2
- NPHMSVBFYLYSCR-UHFFFAOYSA-N 9-[1-[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]azepan-4-yl]-1-oxa-3,9-diazaspiro[4.6]undecan-2-one Chemical compound FC(C1=NOC(=N1)N1CCC(CCC1)N1CCC2(CNC(O2)=O)CCC1)(F)F NPHMSVBFYLYSCR-UHFFFAOYSA-N 0.000 claims description 2
- CXBFWSRCRSBFFY-UHFFFAOYSA-N 9-[1-[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]azepan-4-yl]-2,9-diazaspiro[4.6]undecan-3-one Chemical compound FC(C1=NOC(=N1)N1CCC(CCC1)N1CCC2(CC(NC2)=O)CCC1)(F)F CXBFWSRCRSBFFY-UHFFFAOYSA-N 0.000 claims description 2
- RYBXCSUPAKBJPR-UHFFFAOYSA-N 9-[2-(3-methyl-1,2,4-oxadiazol-5-yl)-2-azabicyclo[2.2.2]octan-5-yl]-1-oxa-3,9-diazaspiro[4.6]undecan-2-one Chemical compound CC1=NOC(=N1)N1C2CC(C(C1)CC2)N1CCC2(CNC(O2)=O)CCC1 RYBXCSUPAKBJPR-UHFFFAOYSA-N 0.000 claims description 2
- PUFQPKPLGSCLKV-UHFFFAOYSA-N 9-[6-(3-methyl-1,2,4-oxadiazol-5-yl)-6-azabicyclo[3.2.1]octan-3-yl]-1-oxa-3,9-diazaspiro[4.6]undecan-2-one Chemical compound CC1=NOC(=N1)N1C2CC(CC(C1)C2)N1CCC2(CNC(O2)=O)CCC1 PUFQPKPLGSCLKV-UHFFFAOYSA-N 0.000 claims description 2
- KXTZOGUEIMZHJD-UHFFFAOYSA-N 9-[8-(3-methyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl]-1-oxa-3,9-diazaspiro[4.6]undecan-2-one Chemical compound CC1=NOC(=N1)N1C2CC(CC1CC2)N1CCC2(CNC(O2)=O)CCC1 KXTZOGUEIMZHJD-UHFFFAOYSA-N 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 239000004215 Carbon black (E152) Substances 0.000 claims description 2
- 206010065390 Inflammatory pain Diseases 0.000 claims description 2
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 2
- 201000002832 Lewy body dementia Diseases 0.000 claims description 2
- 208000028017 Psychotic disease Diseases 0.000 claims description 2
- YWADPRXIMRFCNF-OMOCHNIRSA-N [(2R)-4,4-difluoro-1-[1-[1-(3-methyl-1,2,4-oxadiazol-5-yl)azepan-4-yl]piperidin-4-yl]pyrrolidin-2-yl]methanol Chemical compound FC1(C[C@@H](N(C1)C1CCN(CC1)C1CCN(CCC1)C1=NC(=NO1)C)CO)F YWADPRXIMRFCNF-OMOCHNIRSA-N 0.000 claims description 2
- MLFLWHHYWOXSMP-IFJNFQAOSA-N [(2R,4R)-4-fluoro-1-[1-[1-(3-methyl-1,2,4-oxadiazol-5-yl)azepan-4-yl]piperidin-4-yl]pyrrolidin-2-yl]methanol Chemical compound F[C@@H]1C[C@@H](N(C1)C1CCN(CC1)C1CCN(CCC1)C1=NC(=NO1)C)CO MLFLWHHYWOXSMP-IFJNFQAOSA-N 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 230000001149 cognitive effect Effects 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- ZAJNGDIORYACQU-UHFFFAOYSA-N decan-2-one Chemical compound CCCCCCCCC(C)=O ZAJNGDIORYACQU-UHFFFAOYSA-N 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 claims description 2
- 229930195733 hydrocarbon Natural products 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 230000000926 neurological effect Effects 0.000 claims description 2
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023158190A JP2023164721A (ja) | 2018-06-22 | 2023-09-22 | ムスカリンｍ１および／またはｍ４受容体のアゴニストとしてのオキサジアゾール |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1810245.9 | 2018-06-22 | ||
| GBGB1810245.9A GB201810245D0 (en) | 2018-06-22 | 2018-06-22 | Pharmaceutical compounds |
| PCT/GB2019/051778 WO2019243850A1 (en) | 2018-06-22 | 2019-06-24 | Oxadiazoles as agonists of the muscarinic m1 and/or m4 receptor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023158190A Division JP2023164721A (ja) | 2018-06-22 | 2023-09-22 | ムスカリンｍ１および／またはｍ４受容体のアゴニストとしてのオキサジアゾール |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021528447A JP2021528447A (ja) | 2021-10-21 |
| JPWO2019243850A5 true JPWO2019243850A5 (es) | 2022-07-01 |
| JP7389762B2 JP7389762B2 (ja) | 2023-11-30 |
Family
ID=63042556
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020571700A Active JP7389762B2 (ja) | 2018-06-22 | 2019-06-24 | ムスカリンｍ１および／またはｍ４受容体のアゴニストとしてのオキサジアゾール |
| JP2023158190A Pending JP2023164721A (ja) | 2018-06-22 | 2023-09-22 | ムスカリンｍ１および／またはｍ４受容体のアゴニストとしてのオキサジアゾール |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023158190A Pending JP2023164721A (ja) | 2018-06-22 | 2023-09-22 | ムスカリンｍ１および／またはｍ４受容体のアゴニストとしてのオキサジアゾール |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10858352B2 (es) |
| EP (1) | EP3810607A1 (es) |
| JP (2) | JP7389762B2 (es) |
| KR (1) | KR20210024036A (es) |
| CN (1) | CN112585135B (es) |
| AU (1) | AU2019289216B2 (es) |
| BR (1) | BR112020026437A2 (es) |
| CA (1) | CA3104085A1 (es) |
| GB (1) | GB201810245D0 (es) |
| MX (1) | MX2020014156A (es) |
| SG (1) | SG11202012570TA (es) |
| TW (1) | TW202019918A (es) |
| WO (1) | WO2019243850A1 (es) |
| ZA (1) | ZA202007986B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2619829T3 (es) | 2011-11-18 | 2017-06-27 | Heptares Therapeutics Limited | Agonistas del receptor muscarínico M1 |
| GB201513743D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
| GB201810245D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB202020191D0 (en) * | 2020-12-18 | 2021-02-03 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| CN114555606B (zh) | 2019-10-09 | 2024-10-01 | 诺华股份有限公司 | 作为m4激动剂的5-氧杂-2-氮杂螺[3.4]辛烷衍生物 |
| CR20220141A (es) * | 2019-10-09 | 2022-05-03 | Novartis Ag | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999032486A1 (en) * | 1997-12-23 | 1999-07-01 | Alcon Laboratories, Inc. | Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions |
| US7786141B2 (en) | 2004-08-19 | 2010-08-31 | Vertex Pharmaceuticals Incorporated | Dihydrospiroindene modulators of muscarinic receptors |
| JP2009521483A (ja) | 2005-12-22 | 2009-06-04 | バーテックス ファーマシューティカルズ インコーポレイテッド | ムスカリン受容体のモジュレーター |
| EP1987034B1 (en) | 2006-02-22 | 2011-07-20 | Vertex Pharmceuticals Incorporated | Spiro condensed piperidines as modulators of muscarinic receptors |
| WO2008021375A2 (en) | 2006-08-15 | 2008-02-21 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
| WO2008117229A1 (en) * | 2007-03-23 | 2008-10-02 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
| SG188985A1 (en) * | 2010-09-17 | 2013-05-31 | Array Biopharma Inc | Piperidinyl-substituted lactams as gpr119 modulators |
| CN104640851B (zh) | 2012-09-18 | 2017-05-31 | 赫普泰雅治疗有限公司 | 作为毒蕈碱的m1受体激动剂的二环氮杂化合物 |
| WO2014122474A1 (en) | 2013-02-07 | 2014-08-14 | Takeda Pharmaceutical Company Limited | Piperidin-1 -yl and azepin-1 -yl carboxylates as muscarinic m4 receptor agonists |
| EP4413985A2 (en) * | 2014-02-06 | 2024-08-14 | Nxera Pharma UK Limited | Pharmaceutical compounds |
| GB201404922D0 (en) | 2014-03-19 | 2014-04-30 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201513743D0 (en) * | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201513742D0 (en) * | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201617454D0 (en) * | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
| GB201810245D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
-
2018
- 2018-06-22 GB GBGB1810245.9A patent/GB201810245D0/en not_active Ceased
-
2019
- 2019-06-24 AU AU2019289216A patent/AU2019289216B2/en active Active
- 2019-06-24 EP EP19734158.9A patent/EP3810607A1/en active Pending
- 2019-06-24 KR KR1020217001748A patent/KR20210024036A/ko not_active Application Discontinuation
- 2019-06-24 SG SG11202012570TA patent/SG11202012570TA/en unknown
- 2019-06-24 CN CN201980054880.1A patent/CN112585135B/zh active Active
- 2019-06-24 TW TW108122031A patent/TW202019918A/zh unknown
- 2019-06-24 US US16/450,279 patent/US10858352B2/en active Active
- 2019-06-24 BR BR112020026437-7A patent/BR112020026437A2/pt unknown
- 2019-06-24 JP JP2020571700A patent/JP7389762B2/ja active Active
- 2019-06-24 MX MX2020014156A patent/MX2020014156A/es unknown
- 2019-06-24 CA CA3104085A patent/CA3104085A1/en active Pending
- 2019-06-24 WO PCT/GB2019/051778 patent/WO2019243850A1/en active Application Filing
-
2020
- 2020-10-13 US US17/069,070 patent/US11319312B2/en active Active
- 2020-12-21 ZA ZA2020/07986A patent/ZA202007986B/en unknown
-
2023
- 2023-09-22 JP JP2023158190A patent/JP2023164721A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11878975B2 (en) | Substituted indole compounds useful as TLR inhibitors | |
| JP2023087045A (ja) | ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物 | |
| US7538132B2 (en) | Isoxazolo derivatives | |
| JP4783867B2 (ja) | β３アドレナリン受容体アゴニストとしてのヒドロキシメチルピロリジン | |
| JP4749715B2 (ja) | Ｎ−アリールジアザスピロ環式化合物、並びにその製造及び使用方法 | |
| RU2448105C2 (ru) | 2-аминобензоксазолкарбоксамиды в качестве модуляторов 5-нт3 | |
| CN112585135B (zh) | 作为毒蕈碱m1和/或m4受体的激动剂的噁二唑 | |
| CN110903306A (zh) | 毒蕈碱受体激动剂 | |
| JP2018522034A5 (es) | ||
| JP2020523396A5 (es) | ||
| RU2008115268A (ru) | Индазолы, бензотиазолы, бензоизотиазолы, бензоизоксазолы, пиразолопиридины, изотиазолопиридины, их получение и их применение | |
| JP2009527569A (ja) | ムスカリン受容体の調節剤 | |
| JPWO2019243850A5 (es) | ||
| EP3980412A2 (en) | 1-pyrazolyl, 5-, 6- disubstituted indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof | |
| US8198296B2 (en) | Sub-type selective azabicycloalkane derivatives | |
| EP1542999A1 (en) | 1h-pyrazole and 1h-pyrrole-azabicyclic compounds with alfa-7 nachr activity | |
| WO1999042452A1 (fr) | Derives de phtalazine et remedes contre la dyserection | |
| US20230023559A1 (en) | Arylmethylene heterocyclic compounds as kv1.3 potassium shaker channel blockers | |
| JPWO2019243851A5 (es) | ||
| RU2020141712A (ru) | Оксадиазолы в качестве агонистов мускаринового рецептора m1 и/или m4 | |
| WO2020096916A2 (en) | Inhibitors of histone deacetylase useful for the treatment or prevention of hiv infection | |
| JP3947627B2 (ja) | フタラジン誘導体および勃起機能不全症治療剤 |